Cerence Inc. heads into its May 8 earnings print with options traders overwhelmingly bullish — a sharp contrast to a short interest position that remains stubbornly elevated.
The most striking signal heading into the report is in the options market. The put/call ratio has dropped to 0.44, more than two standard deviations below its 20-day average of 0.55 — a reading near the most call-skewed extreme of the past year. That is not defensive positioning. It reflects a concentrated bet on upside, likely tied to the stock's 40% rally over the past month to $10.54. Call buyers have piled in even as the stock recovered sharply, suggesting conviction that the print either sustains or extends the move.
Short interest tells a different story — one of persistence rather than panic. At 13.3% of free float, the short position remains substantial. It edged down roughly 1.4% over the past month but barely moved this week, with just a fraction of a percent change on the day before earnings. At 9.5 days to cover, covering pressure could be acute if the report surprises to the upside. Notably, borrow availability is ample at nearly 394% of short interest — far from a squeeze setup — and cost to borrow is minimal at 0.51%, meaning shorts face almost no carry pain from holding through the print. The ORTEX short score of 63.5 reflects this ambiguous setup: elevated but not extreme.
The analyst landscape is thin and mixed. Cantor Fitzgerald initiated coverage with an Overweight rating and an $11 target in early April — the sole buy-side conviction on record. Goldman Sachs holds a Neutral, having trimmed its target to $8 back in February, though the stock has since blown past that level. With the mean price target at $10.25 and the stock trading at $10.54, the print has already forced the Street's hand: Cerence is trading above consensus. On fundamentals, analysts project roughly $314M in revenue and normalized net income of around $28M. The EV/EBITDA multiple of around 9x is not demanding given a 12-month forward EPS growth rank in the 92nd percentile of the universe — the market appears to be pricing in a recovery narrative.
The institutional base offers modest comfort. BlackRock and Vanguard both added shares in recent months, and Dimensional and State Street also increased positions — quiet accumulation from passive and quantitative managers. The insider picture is dated (all trades trail back to October 2025 and earlier), so it adds little to the current setup.
With the stock already pricing in a recovery, call buyers leaning hard on further upside, and a meaningful short base that could be forced to cover quickly, the earnings report will test whether Cerence's operational improvement is real enough to justify a valuation that the Street has already struggled to keep up with.
See the live data behind this article on ORTEX.
Open CRNC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
